Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Current Deferred Revenue (2020 - 2021)

Atea Pharmaceuticals' Current Deferred Revenue history spans 2 years, with the latest figure at $192.2 million for Q3 2021.

  • Quarterly Current Deferred Revenue changed N/A to $192.2 million in Q3 2021 from the year-ago period, while the trailing twelve-month figure was $192.2 million through Sep 2021, changed N/A year-over-year, with the annual reading at $301.4 million for FY2020, N/A changed from the prior year.
  • Current Deferred Revenue came in at $192.2 million for Q3 2021, down from $225.0 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $301.4 million in Q4 2020 to a low of $192.2 million in Q3 2021.